Topical Ruxolitinib in Acute Skin GVHD (Graft Versus Host Disease)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The purpose of this study is to see if ruxolitinib, a Janus Kinase (JAK) 1/2 inhibitor, is safe for people who have acute skin graft versus host disease (GVHD) following allogenic hematopoietic stem cell transplantation (HSCT).
Epistemonikos ID: a9f11608b690a0973060b5b3e680f4a946b40fb4
First added on: Sep 03, 2026